sign in sign up
<<
Home , AmFAR, Bizarre Love Triangle, Kenneth Cole Productions, Mathilde Krim

Annual Report 2016 amfAR,The Foundation for AIDS Research Contents

amfAR in 2016 01

Grants, Fellowships, and Awards 07

Research Grants, Fellowships, and Awards

TREAT Asia Grants and Awards

GMT Initiative Awards

Public Policy Awards

Financial Highlights 13

Leadership and Advisory Committees 15

Board of Trustees

Scientific Advisory Committee

Program Advisory Council

Management Group

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research. amfAR in 2016 amfAR CEO Kevin Robert Frost flanked by Dr. Paul Volberding, director of the amfAR Institute for HIV Cure Research (left), and amfAR Chairman

Research u ARCHE, the amfAR Research Consortium on HIV Eradication, Countdown to a Cure for AIDS was launched in 2010. It supports collaborative teams of scientists in the U.S. and around the world working on a range of In 2015, amfAR announced a $100 million investment strategy to HIV cure strategies. support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by 2020. The strategy u The Opportunity Fund is a funding mechanism that enables represents an unprecedented expansion of amfAR’s grant making amfAR to respond quickly to emerging and unforeseen research and is designed to provide support to any scientist or team of opportunities. investigators for any research idea with the potential to advance the search for a cure, at any stage of its development. Innovation Grants In just the first 24 months of the initiative, amfAR has supported 139 principal investigators and key personnel in 16 U.S. states and nine In June 2016, amfAR announced a new round of Innovation Grants, other countries around the world. Structured to provide sustained totaling close to $1.4 million, to allow scientists to better understand support for a wide range of studies that advance both emerging and why HIV persists in the body despite effective antiretroviral therapy established ideas, the strategy comprises the following components: and pursue novel pathways to a cure. The grants were supported in part by the Foundation for AIDS and Immune Research (FAIR). u The amfAR Institute for HIV Cure Research, established in Among the grantees are Dr. Jonathan Karn of Case Western 2016 with a $20 million grant over five years to the University of Reserve University in Cleveland, who is aiming to develop a more California, (UCSF), is the cornerstone of amfAR’s accurate, cost-effective, and efficient way to measure the size of the cure research efforts. viral reservoir; Dr. Maud Mavigner of Emory University in Atlanta, who is conducting a comprehensive study to identify the most u Innovation Grants, two-year awards of up to $200,000 each that accurate methods to measure the viral reservoir in rhesus macaques enable researchers to test innovative ideas supported by limited infected with SIV (the simian form of HIV); and Dr. Celsa Spina of the preliminary data. University of California, San Diego, who is studying how and where u Impact Grants of up to $2 million each over four years support HIV inserts itself into our DNA, enabling it to establish the hidden the in-depth development of concepts already underpinned by viral reservoir. preliminary data showing genuine potential for achieving a cure. Investment Grants u Investment Grants are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. These $1 In January 2016, amfAR awarded $1 million each over four years million grants are awarded over a four-year period. Grantees to Harvard physicist Dr. David Weitz and bioengineer and polymer may have expertise in fields such as cancer, neuroscience, or scientist Dr. Alexander Zelikin of Aarhus University in Denmark. inflammatory disease that can directly inform efforts to cure HIV. The two are collaborating with leading HIV researchers Drs. Bruce Walker and Martin Tolstrup at Harvard and Aarhus, respectively, in

1 their efforts to eradicate the viral reservoir, which is considered the The 2016 fellows are Dr. Luis Agosto of Boston Medical Center, principal barrier to curing HIV. who is exploring one of the mechanisms that perpetuates the viral reservoir, with the goal of understanding how the virus evades the

immune system; Dr. Liang Shan of Yale University, who is using a ARCHE (amfAR Research Consortium humanized mouse model to test the efficacy of latency reversing on HIV Eradication)

In October 2015, amfAR provided $850,000 of renewal ARCHE funding to a consortium of European researchers who aim to replicate the case of the “ patient,” the first and only person known to have been cured of HIV. Diagnosed with leukemia, the patient was given a stem cell transplant with a twist: the cells he received were taken from a donor with a rare genetic mutation conferring resistance to HIV infection. Led by Dr. Javier Martínez- Picado of IrsiCaixa in Spain and Dr. Annemarie Wensing of University Medical Center Utrecht in the Netherlands, the team has already identified a group of patients who have undergone transplants and continues to monitor their progress in the hopes of generating new knowledge that can inform more widely applicable interventions. amfAR also awarded a $672,000 ARCHE grant in June 2016 to support a research team led by Dr. Timothy Schacker of the University of Minnesota, Minneapolis. Schacker is collaborating Dr. Javier Martínez-Picado of IrsiCaixa in Spain with a pair of leading investigators from the amfAR Institute for HIV Cure Research, Drs. Steven Deeks and Peter Hunt of the University drugs, studying their ability to reactivate HIV so that the immune of California, San Francisco (UCSF), to address one of the greatest system can kill those cells that harbor the virus; Dr. Louise Scharf of challenges in HIV cure research: how to establish whether a person the California Institute of Technology in Pasadena, who is studying has been cured. the molecular structure of broadly neutralizing antibodies isolated from two HIV-infected patients to better understand how these Fellowships powerful antibodies can help in the development of a vaccine against the virus; and Dr. Amit Sharma of the Fred Hutchinson In October 2015, amfAR awarded a total of $600,000 in Mathilde Cancer Research Center in Seattle, who is investigating how Krim Fellowships in Basic Biomedical Research, which provide rhesus macaques can be better utilized as an animal model in funding for exceptional young researchers who are new to the field HIV vaccine studies. of HIV/AIDS research. The program, which was created in 2008 in honor of amfAR’s Founding Chairman Dr. Mathilde Krim, has Published Research achieved spectacular results, including numerous published studies in major scientific journals. Each Krim Fellow receives $150,000 over Research studies make the greatest impact on the HIV/AIDS field two years. and on the broader scientific community when they are published in scientific journals. In FY2016, 64 scientific publications resulted from amfAR-funded research.

HIV Cure Summit

In December 2015, amfAR held its second annual HIV Cure Summit at the University of California, San Francisco (UCSF), where leading amfAR-funded HIV cure researchers reported on their progress and discussed the scientific challenges that continue to stand in the way of a cure. The summit followed a November 30 press conference announcing the establishment of the amfAR Institute for HIV Cure Research with a $20 million grant over five years to UCSF. Speaking at the summit, Drs. Warner Greene, Mike McCune, Satish Pillai, and Steven Deeks addressed the four pillars of HIV cure research: charting the locations of latent HIV reservoirs; understanding how these pockets of virus are established and maintained; recording the amount of virus they contain; and finding a way to eliminate them. amfAR Institute for HIV Cure Research scientist Dr. Nadia Roan of the University of California, San Francisco (UCSF)

2 Think Tanks database informs the development of more effective research and treatment programs, and helps define treatment standards specific In March 2016, amfAR hosted a think tank in Memphis, TN, on to HIV/AIDS in Asia. The TAHOD-Lite database, launched by TREAT measuring the latent HIV reservoir. One of the central challenges Asia in 2015, includes more basic data but from a much larger in determining whether a person has been cured is measuring proportion of the HIV-positive patients seen at participating sites. small amounts of virus in difficult-to-find niches. The researchers discussed multiple approaches to address the issue and helped A Global Collaboration design a project that amfAR funded in June 2016, which is being led by think tank participant Dr. Timothy Schacker of the University of For the past 10 years, amfAR’s TREAT Asia program has been Minnesota, Minneapolis. leading the Asia-Pacific region’s involvement in the U.S. National Institutes of Health’s (NIH’s) global HIV consortium, IeDEA—the amfAR hosted another think tank in Portland, OR, in June 2016, on International Epidemiologic Databases to Evaluate AIDS. In 2016, gene therapy approaches to curing HIV. While pharmacological and amfAR successfully re-competed for funding for a new five-year immunological approaches remain the dominant cure strategies, cycle. Studies will be conducted across 58 institutions in 13 the case of the “Berlin patient”—the first and only person known countries to address emerging and critical issues facing people to have been cured of HIV—points to the promise of gene therapy. living with HIV who are transitioning from pediatric to adolescent The 10 researchers discussed the various gene therapy strategies care, and aging into older adults. currently being pursued and developed recommendations for further advancing the field. The new funding will also expand TREAT Asia’s research portfolio to evaluate mental health issues for adolescents, explore how amphetamine use impacts HIV risk behaviors among men who TREAT Asia have sex with men and transgender individuals, and enhance the use of eHealth technologies to engage and retain people in amfAR’s TREAT Asia (Therapeutics Research, Education, and treatment programs. AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children Improving Care for Children across the Asia-Pacific through research, education, and advocacy TREAT Asia’s Pediatric Network includes 20 sites in six countries; of evidence-based HIV-related policies. The TREAT Asia Network these sites share information and best practices in an effort to encompasses 21 adult and 20 pediatric sites throughout the region, improve the quality of pediatric care in the region. The TREAT which collaborate on a variety of projects. TREAT Asia scientists Asia Pediatric HIV Observational Database was modeled on the produced a record 34 publications in peer-reviewed medical adult database and includes data from more than 6,400 pediatric journals in 2016. patients in , , , , , and . Gathering Critical Information

TREAT Asia pioneered the region’s first adult observational Adolescent Research database for HIV/AIDS—the TREAT Asia HIV Observational There has been growing recognition that the global HIV community Database (TAHOD)—which now includes anonymous data has not done enough to prepare patients, families, and providers collected from approximately 10,000 patients at 21 clinical sites in for the transition of children into adult life and from pediatric 12 countries. The information gathered and analyzed through the to adult HIV care. TREAT Asia is helping to develop and fund adolescent transition programs with the Children and Youth Program of SEARCH (South East Asia Research Collaboration on HIV) at the Thai Red Cross AIDS Research Centre (TRC-ARC) with additional funding from LIFE+ and the International AIDS Society’s Collaboration on Paediatric HIV Education and Research (CIPHER) initiative. In 2016, TREAT Asia/amfAR was awarded a two-year Developmental Research Grant by the National Institutes of Health (NIH) to improve the collection of data on adolescent transition in Malawi, , and Thailand.

In 2016, three TREAT Asia investigators, Drs. Tavitiya Sudjaritruk, Suvaport Anugulruengkitt, and Watsamon Jantarabenjakul, were awarded prestigious grants under the CIPHER initiative to research medical problems experienced by HIV-positive youth. In addition, Dr. Nadia Kancheva-Landolt of HIV-NAT at the TRC-ARC conducted several studies aimed at improving the reproductive health of HIV-positive young women in Thailand, with funding Participants at the May 2016 hepatitis C and HIV co-infection treatment from ViiV Healthcare. TREAT Asia has also been following 248 training in HIV-infected adolescents at nine sites in Malaysia, Thailand, and

3 Taking on Hepatitis C Co-Infection

In May 2016, TREAT Asia co-sponsored a training session in Bangkok for clinicians on treating hepatitis C and HIV co-infection with direct-acting antivirals. TREAT Asia conducted the training in collaboration with the International Network for Hepatitis in Substance Users and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. In August 2016, TREAT Asia hosted its fourth regional strategic meeting on hepatitis C virus treatment access with 22 participants from key population regional networks in eight Asian countries.

Public Policy The Thai Red Cross AIDS Research Centre’s Drs. Nittaya Phanuphak and Informed by thorough research and analysis, amfAR is a highly Praphan Phanuphak at the launch of the Adam’s Love Clinic in Bangkok respected advocate of rational and compassionate AIDS-related public policy. Through its Public Policy Office in Washington, DC, amfAR educates policymakers, the media, and the public about Vietnam to evaluate social, cultural, and behavioral factors that evidence-based policies to address HIV/AIDS in the U.S. and affect treatment adherence. The study, which is being funded by around the world. LIFE+, uses an audio computer-assisted self-interview instrument.

Shaping the Domestic Response to HIV/AIDS Expanding Pre-Exposure Prophylaxis (PrEP) in Thailand In February 2016, amfAR published an infographic titled Small In 2016, amfAR funded a study to assess combination HIV Increase, Big Impact, illustrating the declining purchasing power of prevention needs, including pre-exposure prophylaxis (PrEP) the National Institutes of Health’s (NIH) HIV/AIDS research dollars. among female sex workers in Bangkok and Pattaya, Thailand. The In 2016, the NIH budget was increased by $2 billion, and President research team brings together experts from the Service Workers in Obama proposed a further increase of $825 million for 2017. Group (SWING) Foundation, a Thai advocacy organization for sex However, HIV research funding remained at 2015 levels. An increase workers; Institute for Population and Social Research at Mahidol in HIV research funding in line with the increase in total NIH funding University in Bangkok; Johns Hopkins Bloomberg School of Public would have meant an additional $76.6 million for HIV research for Health; and amfAR. 2017. Such an increase would have allowed the NIH to fund 180 HIV/AIDS studies that could significantly advance HIV prevention, Addressing Unmet Needs in HIV Care treatment, or cure research; 51 clinical trials focused on curing HIV; or a breakthrough prevention trial. In January 2016, TREAT Asia embarked on a think tank project to identify and address gaps in the management of HIV in Asia. The project includes over 20 experts in HIV and other sub-specialties from a dozen countries in the region. The think tanks are focusing on three priority areas: HIV and cardiovascular disease, HIV and liver disease, and HIV and drug resistance.

Mobilizing HIV-Positive Youth

In February and May 2016, TREAT Asia held two Youth ACATA (Asia Community for AIDS Treatment and Advocacy) workshops in Bangkok for young people living with HIV from Cambodia, Indonesia, and Thailand. Launched in 2015 with support from ViiV amfAR’s Christina Chandra, Jack MacAllister, and Jennifer Sherwood Healthcare’s Positive Action for Adolescents program, Youth ACATA pose with the Public Policy Office’s posters and publications at the 2016 aims to educate participants about HIV and antiretroviral therapy International AIDS Conference in Durban, South Africa. and connect them to other HIV-positive youth in the region. Key Populations Promoting Treatment Access for GMT amfAR is dedicated to addressing the needs of the people most vulnerable to HIV infection: men who have sex with men, sex In late 2015, with partial funding from amfAR, the Thai Red Cross workers, people who inject drugs, and transgender individuals. AIDS Research Centre launched the Adam’s Love Clinic for gay In October 2015, amfAR published Towards Defining an HIV men, other men who have sex with men, and transgender individuals Implementation Science Agenda for Key Populations in Low- and (collectively, GMT), as well as the Tangerine Community Health Middle-Income Countries based on a meeting the Foundation Centre—Southeast Asia’s first transgender-specific sexual health hosted in May 2015 to brainstorm how implementation science clinic—both in Bangkok.

4 research might improve HIV outcomes for key populations in resource-limited settings. amfAR published Following the Money to Key Populations, National Priorities, and Evidence-Based Budgeting in June 2016. This report is a qualitative assessment of how and South Africa use health data for budgetary resource allocation.

In July 2016, amfAR published Is PEPFAR Funding for Key Populations Aligned with the Epidemiologic Burden? This report is based on an evaluation of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Worldwide, 40−50% of all HIV infections in adults aged 15−49 occur among key populations. The report concluded that the disproportionate HIV risk, along with poor quality health services, underscores the continuing importance of prioritizing resources and targeted interventions. Kaung Htet Thu of the International HIV/AIDS Alliance Myanmar

Global Health effectiveness of HIV self-testing done in the privacy of one’s home, point-of-care CD4 testing, and the use of “peer navigators” In FY2016, amfAR published The World Without PEPFAR, an familiar with the local health system to help those newly infographic highlighting significant advances in global HIV/AIDS diagnosed gain access to HIV treatment and care. treatment and prevention made possible by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Launched in 2003, u In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud PEPFAR made billions of dollars available for HIV programs in y Educación and his team are aiming to improve the continuum developing countries and fundamentally changed the course of the of care among transgender women by using an innovative model global epidemic. that integrates HIV prevention and treatment services with amfAR also added new features and data to its PEPFAR Country/ transgender-affirming medical care. Regional Operational Plan database, a comprehensive, navigable u And in Bangkok, Dr. Nittaya Phanuphak and her team at the database of PEPFAR’s planned funding of HIV/AIDS activities Thai Red Cross AIDS Research Centre are working to show from 2007 to 2015. Launched in 2015, the database is designed how innovative technologies such as GMT-targeted websites to help civil society organizations, ministries of health and finance, that incorporate online counseling and support can be utilized researchers, and other stakeholders access and understand to increase rates of HIV testing and referrals to prevention and PEPFAR’s programs and priorities on a deeper level than was treatment programs. possible using other platforms.

The GMT Initiative amfAR HIV Scholars Program In FY2016, amfAR supported four young researchers from Paraguay, Since 2007, amfAR has been serving the HIV-related needs of gay Brazil, South Africa, and Indonesia undergoing five months of men, other men who have sex with men, and transgender individuals graduate-level public health study at the Center for LGBT Health (collectively, GMT) throughout the developing world through its Research at the University of Pittsburgh Graduate School of Public GMT Initiative. Through small, targeted grants to grassroots groups, Health as part of the amfAR HIV Scholars Program. The program amfAR has expanded access to HIV education and prevention aims to strengthen GMT community-based research and responses services; supported advocacy aimed at increasing funding for to HIV, often in areas where little data about HIV among GMT prevention and treatment services; and worked to end the stigma, currently exist and where stigma and discrimination deter many from discrimination, and violence that threaten the lives of GMT and fuel seeking HIV testing and services. The 2016 amfAR HIV Scholars the spread of HIV/AIDS. are Dr. Antonio Spagnolo of the National University of Asunción in Paraguay; Daniel Dutra de Barros of Santa Casa de São Paulo Implementation Science Awards School of Medical Sciences in Brazil; Kabelo Maleke of Project Boithato at the Anova Health Institute in rural South Africa; and Adi In FY2016, amfAR’s grant making through the GMT Initiative Nugroho of the GWL-INA Network in Jakarta, Indonesia. evolved to support larger implementation science projects aimed at identifying barriers to HIV testing, treatment, and care and studying the impact of innovative HIV service delivery models for GMT in low- Public Information and middle-income countries. amfAR has awarded $2.6 million over amfAR seeks to translate and disseminate information on important three years to support three such studies. HIV/AIDS-related research, treatment, prevention, and policy u Dr. Chris Beyrer of Johns Hopkins University is leading a team issues for diverse audiences and to increase broad awareness of researchers and community-based services (in collaboration and knowledge of the pandemic. amfAR also publishes a wide with the International HIV/AIDS Alliance Myanmar) in evaluating range of educational materials, maintains an informative website, the effectiveness of promising interventions for GMT in Myanmar, and engages respected public figures, HIV/AIDS scientists, and where increased HIV testing and treatment opportunities policymakers in communicating the need for continued research to are becoming available. The researchers are assessing the develop new methods of prevention, treatment, and, ultimately, a cure for HIV. 5 Educational Materials Enlisting the Help of Public Figures amfAR produces a range of periodicals in both print and electronic amfAR’s public awareness efforts are greatly enhanced by the formats, including its newsletter Innovations, published twice a year committed support of public figures who lend their voices and and distributed to more than 45,000 people; the TREAT Asia Report, donate their time, talents, and resources to help sustain the an email newsletter distributed six times a year to more than 4,000 Foundation’s mission. Support of amfAR by prominent public figures readers in the international health community; and a monthly e-mail began with the late Dame , amfAR’s Founding newsletter distributed to nearly 100,000 people. The Foundation’s International Chairman, and others have followed in her footsteps. website, which attracts an average of 40,000 visitors per month, amfAR is profoundly grateful for the continuing steadfast support of features news, interviews, and original articles covering HIV/AIDS Global Campaign Chair . research, policy, the global epidemic, and amfAR programs and Other celebrity supporters included amfAR Ambassadors Milla activities. amfAR also creates and distributes program reports, press Jovovich, Michelle Yeoh, and Cheyenne Jackson, Kathy Bates, releases, and updates on major HIV/AIDS issues, and conducts Angela Bassett, Julia Roberts, Matt Bomer, Jamie Lee Curtis, public service advertising campaigns that have been instrumental in Diane von Furstenberg, Gwyneth Paltrow, Chiara Ferragni, Ryan educating policymakers, healthcare professionals, people living with Murphy, Lady Gaga, Diane Kruger, , Dame Helen HIV/AIDS, and the general public. Mirren, Faye Dunaway, , Kate Moss, Marc Jacobs, Ricky Martin, Lea Michele, Michelle Rodriguez, , Social Media amfAR Trustee , Naomi Campbell, , Riccardo Tisci, Adrien Brody, Eva Longoria, Harvey Keitel, Leonardo amfAR has vigorously expanded its presence in the social media DiCaprio, Robert De Niro, Robin Thicke, Andrea Bocelli, Dean and arena, reaching large numbers of people, including a younger Dan Caten, Chris Tucker, Jennifer Garner, , and demographic that is often less educated about HIV and the AIDS Carine Roitfeld. epidemic. The Foundation regularly adds content to its Facebook page, live tweets from events, and posts images on Instagram In 2016, of 1980s classic hits was updated by from fundraising and program events. amfAR has 72,000 likes contemporary artists for The Time is Now!—a 14-track compilation on Facebook, 40,000 Twitter followers, and more than 108,000 album to benefit amfAR. The album features a soulful rendition of Instagram followers. Michael Jackson’s “Billie Jean” by singer- Aloe Blacc, and a rendition of New Order’s “Bizarre Love Triangle” performed by Sugar for Sugar, consisting of , Julia Haltigan, Media Outreach Holly Miranda, and Kendra Morris. The band Lower Dens, pop rock In 2016, amfAR continued to work closely with the media to raise group DNCE, Dita Von Teese and Sebastien Tellier, and songwriting the profile of HIV/AIDS, both domestically and internationally, and duo Marian Hill are also featured on the album. to help ensure the accuracy of HIV/AIDS-related press coverage. Articles and reports involving amfAR—many of which included interviews with amfAR staff and spokespeople—were carried in numerous media outlets, including The Times, Forbes, The Advocate, the South Morning Post, CBS Radio, Reuters, and Bloomberg News.

SNAPSHOTS The Broad March 2016 Benefits of The World Without PEPFAR Following the oney to Key Populations Hepatitis C Treatment Snapshots: AIDS Research PEPFAR—the U.S. President’s Emergency Plan for AIDS Relief—was launched under President George W. Bush in 2003. At the time, global investment in HIV programs in developing countries was practically non-existent. The Global Fund to Fight AIDS, Tuberculosis and Malaria was launched in 2002 with funding levels wholly inadequate to address the crisis. Public sector ational Priorities and Ledipasvir + Sofosbuvir treatment programs had not even begun in most African countries as the medications necessary were too expensive and unavailable and there was limited evidence that the infrastructure or human resource capacity necessary to deliver treatment EidenceBased Budgeting programs was adequate. PEPFAR—by making billions of dollars available for HIV programs in developing countries—unlocked edipasvir is a medication used to treat and cure infection EC-approved indications for use the ability to deliver programs and fundamentally changed the course of the HIV/AIDS epidemic and the world more broadly. caused by the hepatitis C virus (HCV). It is given in combination with sofosbuvir as a single, fixed-dose Genotype Population Regimen Duration* Absent this enormously successful program, the world would be a remarkably different place: combination tablet of 90 mg of ledipasvir and 400 mg of Ledipasvir + L 1 and 4 Without cirrhosis 12 weeks sofosbuvir. The tablet is taken a day, has few side effects, sofosbuvir June 2016 INDIVIDUAL OUTCOMES and can be used to treat HCV in people who are co-infected Ledipasvir + with HIV. The World sofosbuvir + 12 weeks With compensated Health Organization 1 and 4 ribavirin cirrhosis In April 2016, the World Health Organization (WHO) (WHO) has included Acronyms: Ledipasvir + Is PEPFAR Funding for Key Populations 24 weeks it in its Model HIV: Human immunodeficiency virus sofosbuvir Fact Sheet on WHO updated its guidelines on screening, care, and treatment List of Essential Peg-IFN: Pegylated interferon With compensated of hepatitis C infection. The guidelines are aimed at 1 Ledipasvir + Medicines. cirrhosis or after liver 1 and 4 sofosbuvir + 12 weeks helping policy makers and healthcare providers in low- Aligned with the Epidemiologic Burden? transplant without ribavirin and middle-income countries establish screening, care, cirrhosis Guidelines for the and treatment programs for individuals infected with the A Qualitative REGULATORY APPROVALS Ledipasvir + Decompensated The ledipasvir and sofosbuvir fixed-dose combination tablet 1 and 4 sofosbuvir + 12 weeks virus. While the 2014 recommendations on screening and More than 13 million more people die of 11.5 million Prevention of mother-to-child transmission cirrhosis Assessment of the was initially approved for use by the Food ribavirin Screening, Care, care remain unchanged, this updated version providesAIDS-related causes, and life expectancy declines to fewer people programs are never properly scaled up. and Drug Administration (U.S. FDA) in October 2014, the Ledipasvir + less than 40 years have access to treatment. 50% of children Cirrhosis and/or evidence-based recommendations for the treatment of European Commission (EC) in November 2014, and the Drug 3** sofosbuvir + 24 weeks die Lifting All Boats: The Broad Benefits of Increased Investments treatment failure hepatitis C using regimens containing only direct-acting in the hardest hit countries in Limited access to treatment born with HIV and left untreated Use of Key Populations Controller General of India (DCGI) in December 2015. These ribavirin Many new treatments for diseases such as cancer, undermines testing efforts before their 2nd birthday and Treatment antivirals (DAAs), where these medicines are available. sub-Saharan Africa in HIV/AIDS Research approvals include treatment for genotypes 1, 3, 4, 5, and 6 of *Includes patients co-infected with HIV. hepatitis and heart disease have arisen from research Data in Domestic HCV and for co-infection with HIV. **The clinical data to support the use of ledipasvir and sofosbuvir in patients with on HIV/AIDS. This fact sheet summarizes the major recommendations. In 2014, language included in every National Institutes of Health (NIH) budget since the early 1990s directing NIH to invest 10% genotype 3 are limited. of Persons with The full guidelines can be accessed at http://who.int/hepatitis/ of its funding in HIV research was removed. In just four years (2014-2017), removal of this language has resulted in 600 million U.S. FDA-approved indications for use INFRASTRUCTURE OUTCOMES fewer dollars being available for NIH HIV research. At the same time, inflation has shrunk the purchasingBudgeting power of NIH HIVPractices in SAFETY AND EFFICACY publications/hepatitis-c-guidelines-2016/en/ research dollars such that our ability to invest in new treatments, prevention tools, and, most importantly, a cure is at its lowest Genotype * Population Regimen Duration** The drug’s safety and efficacy were initially evaluated in three phase 3 clinical trials with a total of 1,952 participants who were Hepatitis C since 2003. HIV research has not only saved the lives of millions of people living with HIV, but has contributedKenya to the and development South Africa Treatment-naïve with Ledipasvir + WHAT DO THE GUIDELINES SAY? 1 12 weeks chronically mono-infected with HCV genotype 1. of new treatments and technologies for a broad range of diseases. Increases in the NIH HIV research budget lift all boats. or without cirrhosis sofosbuvir INNOVATIONS amfar_broad_benefits_5.5x8.5_MECH.indd 1 Screening 10/11/16 11:09 AM Treatment-experienced Ledipasvir + Infection 1 12 weeks without cirrhosis sofosbuvir Clinical trials involving ledipasvir + sofosbuvir Screening is the process that allows individuals to know if they AUGUST 2016 have been infected with the hepatitis C virus. The guidelines Treatment-experienced Ledipasvir + Clinical trial Regimen Population Cure rates* Declining Purchasing Power of NIH HIV / AIDS Research Dollars 1 24 weeks recommend that: with cirrhosis sofosbuvir Without the economies of scale HIV treatment is one of the best Public health systems are at ION-12 Ledipasvir + Genotype 1; G1/12 wks/99% $3.3B • All individuals who have ever been part of a population realized by PEPFAR, the price of drugs interventions for preventing new Treatment-naïve and sofosbuvir ± treatment-naïve G1/24 wks/98% breaking point Ledipasvir + with high rates of hepatitis C infection should be screened and diagnostic tests is not TB infections; without HIV programs $600M 4,5,6 -experienced with or 12 weeks ribavirin trying to provide palliative care and $3.1B sofosbuvir with the hepatitis C antibody test. This includes people signi cantly reduced scaled up through PEPFAR, without cirrhosis 3 treat opportunistic infections in ION-2 Ledipasvir + Genotype 1; G1/12 wks/94% who inject drugs (PWID) and people living with HIV $2.9B TB rates skyrocket the absence of antiretroviral therapy *Approval does not include infections with genotype 3. sofosbuvir ± treatment- G1/24 wks/99% (PLHIV). **Includes patients co-infected with HIV. ribavirin experienced $2.7B • Anyone who has a positive antibody test should have a The Foundation for AIDS Research ION-34 Ledipasvir + Genotype 1; G1/8 wks/94% hepatitis C RNA test (also known as a hepatitis C viral $2.5B sofosbuvir ± treatment-naïve, G1/12 wks/95% STABILITY & CREDIBILITY OUTCOMES load test) to confirm whether or not there is ongoing ribavirin non-cirrhotic $2.3B Harnessing the Power chronic infection. *By genotype (G) and duration in weeks (wks). Cure rates for other patient groups are provided $2.1B Care Published by amfAR in the references. All people with chronic hepatitis C infection can take steps to July 2016 $1.9B Please Visit Us Online at prevent liver damage and should have access to appropriate www.treatasia.orgof Antiodies medical care to monitor the condition of their livers. $1.7B • An alcohol intake assessment should be done for people 2003 2014 2015 2016 2017 Unable to sustainably develop human capital U.S. credibility as a leader on global health Political instability permanently TA_Snapshots_Ledipasvir_030216.indd 1 3/4/16 3:49 PM who have confirmed hepatitis C infection, followed by an or to attract critical foreign investment, and human rights is in sub-Saharan African nations diminished NIH HIV Budget Inflation Adjusted NIH HIV Budget with 10% Set Aside Inflation alcohol reduction intervention for those with moderate many African economies face a for its failure to address the grows significantly, increasing to 2003 Dollars 10% Set Aside Adjusted to 2003 Dollars ould they hold or high alcohol intake (more than nine glasses of beer or catastrophic global health crisis the likelihood of conicts affecting wine per week). downward spiral of the century U.S. security interests • PWID should be offered information on how to prevent the ey to an acquisition of hepatitis B and C infection, including being The Foundation for AIDS Research Many new and Drugs developed to treat HIV are now widely used to treat hepatitis B. offered vaccination against hepatitis B virus to avoid the risk of having two liver infections at the same time. experimental treatments I cure • Liver damage should be assessed using the APRI and Researchers are investigating the use of protease inhibitors—first used FIB-4 scores, which are calculated using a combination of for diseases such as to treat HIV—to treat Alzheimer’s disease. liver enzymes, platelets, and the person’s age.1 A special July 2016 cancer, hepatitis and Also Inside ultrasound of the liver that assesses liver stiffness (called a Alzheimer’s have arisen Experimental treatments for several types of cancer have grown directly FibroScan®) can be used, if available. out of AIDS research. New amfA Grants 1 Online score calculators are available at: from research on http://gihep.com/calculators/hepatology/fibrosis-4-score/ and Adance Cure esearch http://www.hepatitisc.uw.edu/page/clinical-calculators/apri. HIV/AIDS. Here are A new class of anti-HIV drug called a CCR5 inhibitor is being tested for the treatment of certain autoimmune disorders. A Step Forward for HIV just a few examples: Published by amfAR Preention Tests developed to diagnose HIV are now routinely used to detect other Please Visit Us Online at www.treatasia.org diseases such as hepatitis C, TB, and Lyme disease. Improing Pediatric HIV Treatment in Asia TA FS info 060316.indd 1 6/13/16 12:38 PM

amfAR, The Fondation for AIDS Research org

6 2016 RESEARCH GRANTS, INNOVATION GRANTS Rational immunogen design based on study of potent HIV-1 trimer-specific bNAbs FELLOWSHIPS, AND AWARDS Analytic treatment interruption to study viral Principal Investigator: reservoirs and as test for cure in HIV-infected Louise Scharf, PhD adults on ART All projects listed below were awarded California Institute of Technology Principal Investigator: Pasadena, CA funding during the period October 1, 2015, Steven Deeks, MD $150,000 through September 30, 2016. University of California, San Francisco San Francisco, CA Identification, reactivation and elimination of latent HIV-1 in humanized mice 1 $77,764 Supported in part with funds provided by the Principal Investigator: FAIR Foundation Uncovering HIV-1-infected cells: a new path Liang Shan, PhD towards a cure Yale University amfAR INSTITUTE FOR HIV CURE Principal Investigator: New Haven, CT RESEARCH Andrés Finzi, PhD $150,000 Université de Montréal, Centre de Recherche du Principal Investigator: CHUM Determinants of HIV-1 replication in non-human Paul Volberding, MD Montreal, primate models University of California, San Francisco $199,9971 Principal Investigator: San Francisco, CA Amit Sharma, PhD $20,000,000 Hormonal control of latent HIV proviruses Fred Hutchinson Cancer Research Center Principal Investigator: Seattle, WA Jonathan Karn, PhD $146,829 Case Western Reserve University amfAR RESEARCH CONSORTIUM ON HIV Cleveland, OH ERADICATION (ARCHE) $200,0001 PHASE II KRIM FELLOWSHIP GRANTS Predictors of time to viremia with an analytic Quantitative HIV reservoir assay using treatment interruption bar-coded RNA Optimization of anti-HIV antibodies for prevention Principal Investigator: Principal Investigator: Jonathan Karn, PhD and therapy Timothy Schacker, MD Case Western Reserve University Principal Investigator: University of Minnesota Cleveland, OH Stylianos Bournazos, PhD Minneapolis, MN $200,0001 The Rockefeller University $671,846 New York, NY Optimized assays to measure the latent SIV $80,000 Allogeneic stem cell transplant in HIV-1-Infected reservoir in rhesus macaques on ART Individuals Principal Investigator: Identification of transmitted viral determinants of Principal Investigator: Maud Mavigner, PhD HIV pathogenesis Annemarie Wensing, MD, PhD Emory University Principal Investigator: University Medical Center Utrecht Atlanta, GA Dario Dilernia, PhD Utrecht, The Netherlands $200,0001 Emory University $849,910 Atlanta, GA Mechanisms and correlates of post-ART $50,000 treatment control in SIV-infected macaques Development of a humanized superagonist Principal Investigator: Identification of a novel HIV-1 restriction factor antibody to human IL-21 for HIV cure Mirko Paiardini, PhD induced by RNA sensing Principal Investigator: Emory University Principal Investigator: Di Yu, PhD Atlanta, GA Henning Hofmann, PhD Monash University $200,0001 Robert Koch Institute Clayton, Berlin, Germany $225,512 Genomic locations of HIV proviruses responsive $80,000 to latency reversing agents Principal Investigator: Targeting engineered nanoparticles for therapeutic Celsa Spina, PhD purge of HIV-1 reservoir INVESTMENT GRANTS University of California, San Diego Principal Investigator: San Diego, CA Nuria Izquierdo-Useros, PhD Eradicating the HIV reservoir: Using microfluidics $200,0001 Fundación IrsiCaixa to exploit killer T cells Barcelona, Spain Principal Investigator: Discovery of tools to modify the fate of uracilated $50,000 David Weitz, PhD HIV DNA in macrophages Harvard University Principal Investigator: Cambridge, MA James Stivers, PhD $977,114 Johns Hopkins University SCIENTIFIC MEETINGS Baltimore, MD Tandem latency reversal and suicide prodrugs to $200,0001 Conference on Cell & Gene Therapy for eliminate HIV reservoirs HIV Cure (2016) Principal Investigator: Principal Investigator: Alexander Zelikin, PhD Keith Jerome, MD, PhD Aarhus University MATHILDE KRIM FELLOWSHIPS IN Fred Hutchinson Cancer Research Center Aarhus, Denmark BASIC BIOMEDICAL RESEARCH Seattle, WA $962,510 $10,000 HIV cell-to-cell transmission and the establishment of latency International AIDS Conference 2016 Principal Investigator: Principal Investigator: Luis Agosto, PhD Owen Ryan, MPH, MIA Boston Medical Center International AIDS Society Boston, MA Geneva, $150,000 $50,000

7 2016 TREAT ASIA GRANTS St. Vincent’s Hospital Sydney Illawarra Shoalhaven Local Health District Darlinghurst, New South Wales Warrawong, New South Wales AND AWARDS David A. Cooper, MD Katherine Brown, MD $5,4751 $1,350 All projects listed below were awarded Taylor Square Private Clinic UNSW–Sydney funding during the period October 1, 2015, Darlinghurst, New South Wales Sydney, New South Wales through September 30, 2016. Robert Finlayson, MBBS, DipVen, FAChSHM Matthew G. Law, PhD $5,0251 IeDEA Asia-Pacific Research Collaboration: TREAT Asia HIV Observational Database & 1Supported by National Institutes of Health Northern Territory Dept of Health & Community Australia HIV Observational Database cooperative agreement number U01AI069907 with Services, Sexual Health & Blood Borne Virus $256,3851 Program funds from the National Institute of Allergy and Darwin, Northern Territory IeDEA Asia-Pacific Research Collaboration: Infectious Diseases, the Eunice Kennedy Shriver Manoji Gunathilake, MD, MBBS, FAChSHM HIV and aging in TAHOD-LITE National Institute of Child Health and Human $975 $15,0001 Development, the National Cancer Institute, Gladstone Road Medical Centre IeDEA Asia-Pacific Research Collaboration: the National Institute of Mental Health, and the Highgate Hill, Queensland Cancer Studies National Institute on Drug Abuse David Orth, MBBS, DipVen $135,9221 $5,1001 IeDEA Asia-Pacific Research Collaboration: 2 Supported by National Institutes of Health grant Nepean Blue Mountains Local Health District, TREAT Asia Pediatric HIV Observational Database number R01HD073972 funded by the Eunice Blue Mountains Sexual Health and HIV Clinic $175,2251 Kennedy Shriver National Institute of Child Health Katoomba, New South Wales Eva Jackson, MBBS, FAChSHM Effectiveness and tolerability of hepatitis C and Human Development $1,575 treatment in HIV co-infected patients in routine care services in Asia 3 Supported with funds provided by the AIDS Life Nepean Blue Mountains Local Health District, $19,289 Association Nepean Sexual Health Clinic Kingswood, New South Wales Julian Langton-Lockton, MBBS 4 CAMBODIA Supported with funds provided by the Open $1,350 Society Foundations Sexual Health and AIDS Services (SHAIDS) National Center for HIV/AIDS, Dermatology & STDS / Cambodia National Institute 5 Supported with funds provided by ViiV Lismore, New South Wales David Smith, MBBS, DipVen, FAChSHM, of Public Health Healthcare GrapDip BA Phnom Penh $6,0751 Ly Penh Sun, MD, MSc AUSTRALIA TREAT Asia HIV Observational Database (TAHOD) Melbourne Sexual Health Centre $20,0001 AUSTRALIA HIV OBSERVATIONAL DATABASE Clayton, Victoria (AHOD) SITES Tim Read, MBBS, DipVen, FRACGP, FAChSHM, Resistance to Second-line Antiretroviral Therapy EpiDip in HIV-Infected Adults in Asia (TASER-2) 5 O’Brien Street Practice $4,4251 $33,666 Adelaide, South Australia TREAT Asia Pediatric HIV Observational Database William Donohue, MBBS Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital (TApHOD) $1,575 3 Melbourne, Victoria $25,000 Sexual Health and HIV Service In Metro North Jennifer Hoy, MBBS New Hope for Cambodian Children 1 Brisbane, Queensland $5,550 Killeen, TX Diane Rowling, MBBS, RACP, FAChSHM John Tucker $3,6001 Sunshine Coast Hospital and Health Service Nambour West, Queensland Our Village 3 Cairns Sexual Health Service David Sowden, MBBS $20,743 1 Cairns, Queensland $6,375 Our Village and New Hope House Darren Russell, MD $50,000 $5,2501 Northside Clinic (Vic) Pty Ltd North Fitzroy, Victoria RPA Sexual Health Clinic Richard Moore, MBBS Camperdown, New South Wales $7,5001 CHINA David Templeton, MBChB, PhD $675 Royal Perth Hospital Beijing Ditan Hospital Perth, Western Australia Beijing Monash Health - Clayton David Nolan, MBBS, FRACP, PhD Fujie Zhang, MD, MSPH, PhD Clayton, Victoria $5,1751 TREAT Asia HIV Observational Database (TAHOD) Ian Woolley, MBBS, FRACP $16,0001 $5,475 Prahran Market Clinic Pty., Ltd. Prahran, Victoria Queen Elizabeth Hospital D.A. Ellis Pty., Ltd. Norman Roth, MBBS FAChSHM Coffs Harbour, New South Wales $5,7751 Man Po Lee, MBBS David Ellis, MBBS TREAT Asia HIV Observational Database (TAHOD) $675 Sydney Sexual Health Centre, Sydney Hospital including NCD Data Sydney, New South Wales $23,0301 East Sydney Doctors Caroline Thng, MBBS, MRCP Darlinghurst, New South Wales $4,2751 David Baker, MB, ChB, Dip Med, DCH $7,0501 Clinic 468, HNE Sexual Health, Hunter New England Local Health District Holdsworth House Medical Practice Tamworth NEMSC, New South Wales Darlinghurst, New South Wales Nathan Ryder, MD Mark Bloch, MD $900 $5,9251

8 INDIA Ketut Dewi Kumara Wati, MD NEPAL TREAT Asia Pediatric HIV Observational Database Johns Hopkins University at B.J. Medical College (TApHOD) Union C and Sassoon General Hospital $7,5003 Kathmandu Pune Roshan Sapkota Vidya Mave, MD, MPH Persaudaraan Korban Napza Indonesia (PKNI) National Awareness Campaign-NEPAL Epidemiology of HIV/AIDS and associated Jakarta $7,001 comorbidities in a public antiretroviral treatment Edo Agustian (ART) clinic in Pune, India Increasing awareness of hepatitis C with 360 short $150,0001 movie campaign $2,5004 Chennai Antiviral Research and Treatment Clinical Research Institute for Tropical Medicine Research Site, YRG CARE Medical Centre, VHS Muntinlupa City Chennai Rossana Ditangco, MD Nagalingeswaran Kumarasamy, MBBS, PhD TREAT Asia HIV Observational Database (TAHOD) TREAT Asia HIV Observational Database (TAHOD) National Center for Global Health and Medicine including NCD Data including NCD Data Tokyo $22,6401 $22,0401 Junko Tanuma, MD, PhD Resistance to Second-line Antiretroviral Therapy in Resistance to Second-line Antiretroviral Therapy in TREAT Asia HIV Observational Database (TAHOD) $16,0001 HIV-Infected Adults in Asia (TASER-2) HIV-Infected Adults in Asia (TASER-2) $5,9505 $5,0005 Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) TREAT Asia Pediatric HIV Observational Database 5 (TApHOD) $2,000 $7,5003 Tan Tock Seng Hospital Institute of Infectious Diseases MALAYSIA Singapore Pune Oon Tek Ng, MBBS Sanjay Pujari, MD, AAHIVS, MBBS Hospital Likas TREAT Asia HIV Observational Database (TAHOD) TREAT Asia HIV Observational Database (TAHOD) Kota Kinabalu $19,2501 including NCD Data Fong Siew Moy, MBBS $22,4101 TREAT Asia Pediatric HIV Observational Database Resistance to Second-line Antiretroviral Therapy in (TApHOD) HIV-Infected Adults in Asia (TASER-2) Wide Angle Social Development Organization $7,5003 $2,0005 Imphal Rajkumar Nalinikanta Hospital Raja Perempuan Zainab II Improving HBV & HCV prevention & treatment Kota Bharu access in Manipur-Phase IV Nik Khairulddin Nik Yusoff, MBBS $10,060 TREAT Asia Pediatric HIV Observational Database Yonsei University College of Medicine (TApHOD) Seoul $7,5003 Jun Yong Choi, MD, PhD INDONESIA TREAT Asia HIV Observational Database (TAHOD) Pediatric Institute, Hospital Kuala Lumpur including NCD Data Cipto Mangunkusumo General Hospital Kuala Lumpur $18,2901 Jakarta Thahira A. Jamal Mohamed, MBBS Nia Kurniati, MD TREAT Asia Pediatric HIV Observational Database Resistance to Second-line Antiretroviral Therapy in TREAT Asia Pediatric HIV Observational Database (TApHOD) HIV-Infected Adults in Asia (TASER-2) 3 5 (TApHOD) $7,500 $2,000 $7,5003 Penang Hospital Georgetown Evy Yunihastuti, MD, PhD TREAT Asia HIV Observational Database (TAHOD) Revathy Nallusamy, MBBS including NCD Data TREAT Asia Pediatric HIV Observational Database Taipei Veterans General Hospital 1 (TApHOD) $22,900 3 Taipei City $2,500 Wing-Wai Wong, MD Resistance to Second-line Antiretroviral Therapy in Sungai Buloh Hospital TREAT Asia HIV Observational Database (TAHOD) HIV-Infected Adults in Asia (TASER-2) including NCD Data 5 Sungai Buloh $35,156 1 Yasmin Mohamed Gani, MD $23,670 Effectiveness and tolerability of HCV treatment in Study of Transitioning Asian Youth (STAY) Cohort HIV co-infected patients: Treatment $14,5615 $11,603 THAILAND Benedict Lim Heng Sim, MBBS, MRCP Indonesia AIDS Coalition TREAT Asia HIV Observational Database (TAHOD) Chiang Mai University – Research Institute for Jakarta including NCD Data Health Sciences Aditya Wardhana $16,1301 Chiang Mai Hep C – Know it, get tested and beat it! Linda Aurpibul, MD $6,5834 University of Malaya Long-term HBV treatment outcome in HIV-HBV co- Kuala Lumpur infected adolescents receiving tenofovir-containing Sanglah Hospital, Udayana University School of Raja Iskandar Shah Raja Azwa, MBBS ARV regimen Medicine Resistance to Second-line Antiretroviral Therapy in $5,2303 Denpasar, Bali HIV-Infected Adults in Asia (TASER-2) Tuti Parwati Merati, MD, PhD $45,3615 Romanee Chaiwarith, MD, MHS TREAT Asia HIV Observational Database (TAHOD) TREAT Asia HIV Observational Database (TAHOD) including NCD Data Adeeba Kamarulzaman, MBBS, FRACP, FAMM, including NCD Data $22,4401 FASc $23,9901 TREAT Asia HIV Observational Database (TAHOD) Resistance to Second-line Antiretroviral Therapy in including NCD Data Tavitiya Sudjaritruk, MD, ScM, PhD HIV-Infected Adults in Asia (TASER-2) $22,3901 TREAT Asia Pediatric HIV Observational Database $28,2645 (TApHOD) Effectiveness and tolerability of HCV treatment in $15,0003 HIV co-infected patients: Treatment $7,581 9 Peripheral Arterial Diseases among Perinatally HIV- Kiat Ruxrungtham, MD VIETNAM infected Thai Adolescents (PAD study) Effectiveness and tolerability of HCV treatment in $18,4231 HIV co-infected patients: Treatment Bach Mai Hospital $11,421 Hanoi Chiangrai Prachanukroh Hospital Do Duy Cuong, MD, PhD Chiang Rai Thai Red Cross AIDS Research Centre TREAT Asia HIV Observational Database (TAHOD) Rawiwan Hansudewechakul, MD Bangkok including NCD Data TREAT Asia Pediatric HIV Observational Database Tarandeep Anand $22,7201 (TApHOD) The impact of online interventions on the HIV $15,0003 prevention/treatment cascade among MSM and Resistance to Second-line Antiretroviral Therapy in transgender individuals HIV-Infected Adults in Asia (TASER-2) Human Papillomavirus Infection in Perinatally HIV- $21,600 $11,9785 infected Adolescents in Asia $64,0432 Thanyawee Puthanakit, MD Children’s Hospital 1 Supporting HIV-infected Adolescents and Youth in Ho Chi Minh City Study of Transitioning Asian Youth (STAY) Cohort Achieving Successful Transition to Adult Care Tran Ngoc Hanh Dan, MD, MSc 3 $21,690 3 $30,000 Human Papillomavirus Infection in Perinatally HIV- Pacharee Kantipong, MD Mahidol University by Faculty of Medicine Siriraj infected Adolescents in Asia TREAT Asia HIV Observational Database (TAHOD) Hospital $8,7772 including NCD Data Kulkanya Chokephaibulkit, MD $30,0401 Truong Huu Khanh, MD TREAT Asia Pediatric HIV Observational Database TREAT Asia Pediatric HIV Observational Database HIV-NAT / Thai Red Cross AIDS Research Centre (TApHOD) 3 (TApHOD) Bangkok $15,000 $25,0003 Praphan Phanuphak, MD, PhD Understanding adherence, stigma, and behavioral Understanding adherence, stigma, and behavioral Examining the prevalence rate and determinants risk factors of adolescents in TApHOD using of frailty in the HIV positive and negative Thai risk factors of adolescents in TApHOD using ACASI ACASI populations $2,7651 $2,5451 $4,7361,3 Human Papillomavirus Infection in Perinatally HIV- Anchalee Avihingsanon, MD, PhD Children’s Hospital 2 infected Adolescents in Asia Ho Chi Minh City TREAT Asia HIV Observational Database (TAHOD) $49,8392 including NCD Data Do Chau Viet, MD $22,2801 Study of Transitioning Asian Youth (STAY) Cohort TREAT Asia Pediatric HIV Observational Database $24,9581 (TApHOD) Sivaporn Gatechompol, MD $20,0003 Human Papillomavirus Infection in Perinatally HIV- Treatment switch from efavirenz to rilpivirine infected Adolescents in Asia in virologically-suppressed HIV-infected Thai Hung Vuong Hospital $65,6872 adolescents Ho Chi Minh City $14,996 Dang Le Dung Hanh, MD, MA Watsamon Jantarabenjakul, MD Human Papillomavirus Infection in Perinatally HIV- Treatment switch from efavirenz to rilpivirine Ramathibodi Hospital, Mahidol University infected Adolescents in Asia in virologically-suppressed HIV-infected Thai Sasisopin Kiertiburanakul, MD, MHS $13,3372 adolescents TREAT Asia HIV Observational Database (TAHOD) $4,974 including NCD Data National Hospital of Pediatrics $23,1501 Hanoi Stephen Kerr, PhD Nguyen Van Lam, MD, MSc Understanding adherence, stigma, and behavioral Srinagarind Hospital, Khon Kaen University TREAT Asia Pediatric HIV Observational Database risk factors of adolescents in TApHOD using Khon Kaen (TApHOD) ACASI (data management center) Pope Kosalaraksa $20,0003 $9,0001 Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai Study of Transitioning Asian Youth (STAY) Cohort Study of Transitioning Asian Youth (STAY) Cohort adolescents $8,7915 Statistical Analysis Center $12,621 $18,0381 National Hospital of Tropical Diseases Pagakrong Lumbiganon, MD Hanoi Nittaya Phanuphak, MD, PhD TREAT Asia Pediatric HIV Observational Database Nguyen Van Kinh, MD, PhD Human Papillomavirus Infection in Perinatally (TApHOD) TREAT Asia HIV Observational Database (TAHOD) HIV-infected Adolescents in Asia (central lab $8,1003 including NCD Data and data manager) $22,6101 $223,1512 Study of Transitioning Asian Youth (STAY) Cohort $21,2515 Resistance to Second-line Antiretroviral Therapy in Neovaginal and anal HPV and related diseases HIV-Infected Adults in Asia (TASER-2) among post-operative transgender women $26,5685 $35,4551 USA Effectiveness and tolerability of HCV treatment in Wasana Prasitsuebsai, MD, MPH HIV co-infected patients: Treatment Coordinating Center: Prospective Monitoring of Massachusetts General Hospital $9,023 Second-line Antiretroviral Therapy Failure and Boston, MA Resistance in Children Andrea Ciaranello, MD, MPH Vietnam Network of People Living with HIV (VNP+) $32,0755 Estimating the magnitude of the pediatric and Hanoi adolescent HIV epidemic in Thailand Do Dang Dong Thanyawee Puthanakit, MD $59,951 Increase knowledge about HCV diagnosis, and TREAT Asia Pediatric HIV Observational Database care and treatment access in the PLHIV and PWID (TApHOD) community $15,0003 $6,5004 Peripheral Arterial Diseases among Perinatally HIV- infected Thai Adolescents $13,4021

10 2016 GMT INITIATIVE 2016 PUBLIC POLICY GRANTS AND AWARDS AWARDS

All projects listed below were awarded The projects listed below were awarded amfAR funding for the period October 1, amfAR funding during the period October 1, 2015, through September 30, 2016. 2015, through September 30, 2016.

AMFAR HIV SCHOLARS AWARDS UNITED STATES

Designing trans-community led HIV treatment Evaluation of needle exchange distribution policy counseling programs suitable for the needs of Project Director: Susan Sherman, PhD trans populations in South Africa Johns Hopkins University Principal Investigator: Liesl Theron Baltimore, MD Gender DynamiX $60,000 Cape Town, South Africa Improving the health of young black men who $25,000 have sex with men (MSM) Project Director: Jeffrey Crowley Pilot study on HIV among men who have sex with Georgetown University men in Belize Washington, DC Principal Investigator: Erika Castellanos $99,350 Collaborative Network of Persons Living with HIV (C-NET+) PrEP advocacy and demand creation for MSM Belize City, Belize Project Director: Emily Bass $25,000 AIDS Vaccine Advocacy Coalition (AVAC) New York, NY Assessing the efficacy of online HIV home testing $50,600 support service to increase quarterly HIV testing among MSM Developing local strategies to implement safe Principal Investigator: Weibin Cheng injection facilities (SIFs) GZTZ.ORG Project Director: Emily Mariko-Sanders Guangzhou, China Project Inform $25,000 San Francisco, CA $10,000 Identifying barriers in accessing care services for low-adherence to ART by MSM and transgender populations in Pakistan INTERNATIONAL Principal Investigator: Sheryar Kazi NAZ Male Health Alliance Increasing access to services for PLHIV who use Lahore, Pakistan drugs in the Philippines $25,000 Project Director: Cara O’Connor Sustained Health Initiatives of the Philippines Mandaluyong City, Philippines GENERAL GMT INITIATIVE GRANTS $30,000 AND AWARDS A training program for HIV research among MSM in low- and middle-income countries Project Director: Ronald D. Stall, PhD, MPH University of Pittsburgh Pittsburgh, PA $164,000

11 12 Financial Highlights For the year ended September 30, 2016

Public Support and Revenue Public support $ 7,104,647 Special events 22,840,383 Planned giving 4,995,589 Government funding 13,063,451 Investment income and other revenue 2,535,019 Total public support and revenue $ 50,539,089

Expenses Research $ 20,306,002 TREAT Asia 5,276,103 GMT Initiative 1,737,688 Public Policy 2,162,183 Public Information 3,892,270 Total program services $ 33,374,246

Fundraising 6,054,303 Management and general 2,509,982 Total supporting services $ 8,564,285

Total expenses $ 41,938,531

Change in net assets 8,600,558 Net assets, beginning of year 53,038,622

Net assets, end of year $ 61,639,180

Statement of Financial Position

Assets Cash and investments $ 64,039,115 Pledges and receivables, net 10,460,976 Prepaid expenses and other assets 3,297,004 Furniture, equipment, and leasehold improvements, net 2,976,566 Total Assets $ 80,773,661

Liabilities Accounts payable and accrued expenses $ 3,412,592 Grants and fellowships payable, net 2,973,966 Deferred support and refundable advances 10,727,662 Other long-term liabilities 2,020,261 Total liabilities $ 19,134,481

Total net assets 61,639,180

Total liabilities and net assets $ 80,773,661

13 Expenses

Fundraising $ 6,054,303 Management and general 2,509,982 Program 33,374,246

Total $ 41,938,531

Program Expenses

Research $ 20,306,002 TREAT Asia 5,276,103 GMT Initiative 1,737,688 Public Policy 2,162,183 Public Information 3,892,270

Total $ 33,374,246

14 T. Ryan Greenawalt IN MEMORIAM BOARD OF TRUSTEES Managing Director Fiscal year 2016 Ramirez & Co. Dame Elizabeth Taylor President Founding International Chairman Chairman of the Board Harrison Street Productions Kenneth Cole New York, NY Sheldon W. Andelson, Esq. Chairman Arnold W. Klein, M.D. Regan Hofmann Kenneth Cole Productions Mrs. Albert D. Lasker Policy Officer New York, NY Jonathan M. Mann, M.D., M.P.H. U.S. Liaison Office Maxine Mesinger Founding Chairman UNAIDS Pauline Phillips Mathilde Krim, Ph.D. Washington, D.C. Natasha Richardson Adjunct Professor Allan Rosenfield, M.D. Michael J. Klingensmith Mailman School of Public Health Peter Scott, Esq. Publisher and CEO Tom Stoddard Star Tribune New York, NY Joel D. Weisman, D.O. Minneapolis, MN Vice Chairman Kevin McClatchy Patricia J. Matson Chairman of the Board Senior Vice President, Communications (ret.) SPECIAL APPOINTMENTS The McClatchy Company ABC, Inc. Ligonier, PA New York, NY Global Campaign Chair Michele V. McNeill, Pharm.D. Sharon Stone Vice Chairman and Treasurer Chairman John C. Simons Global Fundraising Chairman McNeill Family Foundation Managing Partner Milutin Gatsby Sarasota, FL Corporate Fuel Partners, LLC New York, NY Edward L. Milstein Co-Chairman, Milford Management Secretary amfAR AMBASSADORS Co-Chairman, Emigrant Savings Bank Mervyn F. Silverman, M.D., M.P.H. Partner, Milstein Properties President Cheyenne Jackson New York, NY Mervyn F. Silverman Associates Janet Jackson Crockett, CA Milla Jovovich Cindy D. Rachofsky Liza Minnelli Philanthropist Michelle Yeoh Dallas, TX TRUSTEES Vincent A. Roberti Chairman, Roberti Global, LLC Arlen H. Andelson Managing Director, Roberti Associates Global, LLC COMMITTEES OF THE BOARD Senior Partner (ret.) Washington, D.C. OF TRUSTEES Andelson & Andelson , CA Bill Roedy Executive London, UK Harry Belafonte Kenneth Cole, Chair President Raymond F. Schinazi, Ph.D., D.Sc. Michael J. Klingensmith Belafonte Enterprises, Inc. Frances Winship Walters Professor of Pediatrics Mathilde Krim, Ph.D. New York, NY Director, Laboratory of Biochemical Pharmacology Patricia J. Matson Emory University Vincent A. Roberti David Bohnett Decatur, GA Mervyn F. Silverman, M.D., M.P.H. Chairman John C. Simons David Bohnett Foundation Alan D. Schwartz Beverly Hills, CA Executive Chairman Audit Guggenheim Partners, LLC John Simons, Chair Zev Braun New York, NY R. Martin Chavez, Ph.D. President and CEO T. Ryan Greenawalt Braun Entertainment Group, Inc. Diana L. Taylor Beverly Hills, CA Vice Chair Board Development Solera Capital, LLC Donald A. Capoccia, Co-Chair Jonathan S. Canno New York, NY Patricia J. Matson, Co-Chair New York, NY Arlen Andelson Bill Roedy Donald A. Capoccia Mervyn F. Silverman, M.D., M.P.H. Managing Principal TRUSTEE EMERITUS BFC Partners Communications/Social Media/Marketing Brooklyn, NY Arthur J. Ammann, M.D. Regan Hofmann, Chair President, Global Strategies for HIV Prevention Kenneth Cole R. Martin Chavez, Ph.D. Clinical Professor of Pediatrics T. Ryan Greenawalt Chief Information Officer University of California, San Francisco Patricia J. Matson The Goldman Sachs Group, Inc. San Francisco, CA Kevin McClatchy New York, NY Vincent A. Roberti Bill Roedy Jane B. Eisner President Compensation and Organizational Development The Eisner Foundation John C. Simons, Chair Bel Air, CA Michael J. Klingensmith Kevin McClatchy

15 Finance & Budget Michael J. Klingensmith, Chair Dennis R. Burton, Ph.D. Roger Detels, M.D., M.S. Vincent A. Roberti Professor Professor of Epidemiology John C. Simons Department of Immunology School of Public Health The Scripps Research Institute University of California, Los Angeles Fund Development Vincent A. Roberti, Chair Salvatore T. Butera, D.V.M., Ph.D. Carl W. Dieffenbach, Ph.D. Arlen Andelson Chief Science Officer Director Jonathan S. Canno Scripps CHAVI-ID Division of AIDS (DAIDS) Donald A. Capoccia The Scripps Research Institute National Institute of Allergy and Infectious T. Ryan Greenawalt Diseases Cindy Rachofsky Edward Campbell, Ph.D. National Institutes of Health Raymond F. Schinazi, Ph.D., D.Sc. Assistant Professor Department of Microbiology and Immunology D. Peter Drotman, M.D., M.P.H. Investment School of Medicine Editor-in-Chief Michael J. Klingensmith, Chair Loyola University at Chicago Emerging Infectious Diseases R. Martin Chavez, Ph.D. Centers for Disease Control and Prevention T. Ryan Greenawalt Alex Carballo-Dieguez, Ph.D. Edward L. Milstein Co-Director and Senior Research Scientist Anke A. Ehrhardt, Ph.D. Vincent A. Roberti HIV Center for Clinical and Behavioral Studies Director John C. Simons New York State Psychiatric Institute Division of Gender, Sexuality, & Health Columbia University Program for the Study of LGBT Health NYS Psychiatric Institute/Columbia University Nicolas Chomont, Ph.D. Assistant Professor Jacob Estes, Ph.D. Microbiology and Immunology Principal Scientist/Principal Investigator SCIENTIFIC ADVISORY Université de Montréal, Centre de Recherche du AIDS and Cancer Virus Program (ACVP) CHUM Frederick National Laboratory for Cancer Research COMMITTEE National Cancer Institute David B. Clifford, M.D. Professor Homayoon Farzadegan, Ph.D. Daniel C. Douek, M.D., Ph.D. (Chair) Department of Neurology Professor Chief, Human Immunology Section Washington University School of Medicine Department of Epidemiology Vaccine Research Center Johns Hopkins Bloomberg School of Public Health National Institute of Allergy and Infectious C. Budd Colby, Ph.D. Diseases Principal Dianne M. Finkelstein, Ph.D. National Institutes of Health Colby Biomedical Ventures Professor of Biostatistics Harvard School of Public Health Galit Alter, Ph.D. Grant Colfax, M.D. Director of the Cancer Center Biostatics Associate Professor Director Massachusetts General Hospital Department of Medicine Marin Health and Human Services Harvard Medical School San Rafael, California Gerald Herbert Friedland, M.D. Professor and Director Deborah Anderson, Ph.D. Elizabeth Connick, M.D. AIDS Care Program Professor of Obstetrics/Gynecology Professor of Medicine Department of Internal Medicine and Microbiology Chief, Division of Infectious Diseases Yale School of Medicine Boston University School of Medicine Department of Medicine University of Arizona Rémi Fromentin, Pharm.D., Ph.D. Jintanat Ananworanich, M.D., Ph.D. Postdoctoral Researcher Associate Director for Therapeutics Research Deborah Jean Cotton, M.D., M.P.H. Université de Montréal, Centre de Recherche du U.S. Military HIV Research Program Professor of Medicine CHUM Boston University School of Medicine Warren A. Andiman, M.D. Howard E. Gendelman, M.D. Professor Emeritus of Pediatrics Bryan R. Cullen, Ph.D., D.Sc. Professor and Chair, Department of Pharmacology Co-Director, Yale Adoption Clinic James B. Duke Professor and Experimental Neuroscience Medical Director, Pediatric AIDS Care Program Department of Molecular Genetics and Margaret R. Larson Professor of Internal Medicine Yale School of Medicine Microbiology and Infectious Diseases Director, Duke University Center for Virology Director, Center for Neurodegenerative Disorders Eric Arts, Ph.D. Duke University Medical Center University of Nebraska Medical Center Professor Department of Microbiology and Immunology Susanna Cunningham-Rundles, Ph.D. Nancy L. Haigwood, Ph.D. The University of Western Ontario Professor Emerita of Research Immunology Director and Senior Scientist Department of Pediatrics Division of Pathobiology and Immunology Livio Azzoni, Ph.D. Weill Cornell Medical College Oregon National Primate Research Center Senior Staff Scientist Oregon Health and Science University The Wistar Institute Richard Thomas D’Aquila, M.D. Philadelphia, PA The Howard Taylor Ricketts Professor of Medicine Timothy Henrich, M.D. Division of Infectious Diseases Assistant Professor of Medicine Michael Betts, Ph.D. Director, Northwestern HIV Translational Division of Infectious Disease Associate Professor Research Center University of California, San Francisco Department of Microbiology Feinberg School of Medicine Perelman School of Medicine Northwestern University Charles H. Hinkin, Ph.D. University of Pennsylvania Professor Steven Deeks, M.D. Department of Psychiatry and Biobehavioral Jason Brenchley, Ph.D. Professor Sciences Senior Investigator Department of Medicine David Geffen School of Medicine Immunopathogenesis Section University of California, San Francisco University of California, Los Angeles National Institute of Allergy and Infectious Diseases Sherry Deren, Ph.D. David Ho, M.D. National Institutes of Health Co-Director Scientific Director, Chief Executive Officer Center for Drug Use and HIV Research Aaron Diamond AIDS Research Center New York University College of Nursing 16 Thomas J. Hope, Ph.D. Sharon Lewin, F.R.A.C.P., Ph.D. Savita Pahwa, M.D. Professor Director Professor of Microbiology and Immunology Department of Cell and Molecular Biology Peter Doherty Institute for Infection and Immunity Professor in Pediatrics and Medicine Feinberg School of Medicine University of Melbourne Director of the Miami Center for AIDS Research Northwestern University University of Miami Leonard M. Miller School of Mathias Lichterfeld, M.D. Medicine Shiu-Lok Hu, Ph.D. Assistant Professor of Medicine Professor Massachusetts General Hospital Tristram G. Parslow, M.D., Ph.D. School of Pharmacy William Patterson Timmie Professor and Chair University of Washington Judy Lieberman, M.D., Ph.D. Department of Pathology and Laboratory Medicine Senior Investigator Emory University School of Medicine Jonathan Karn, Ph.D. Immune Disease Institute Director Professor of Pediatrics Matija Peterlin, M.D. Center for AIDS Research Harvard Medical School Professor of Medicine, Microbiology and Case Western Reserve University Immunology H. Kim Lyerly, M.D. Department of Medicine Vineet KewalRamani, Ph.D. Professor in Surgery, Immunology, Pathology University of California, San Francisco Chief, Model Development Section George Barth Geller Chair of Cancer Research HIV Drug Resistance Program Director of the Center of Applied Therapeutics Lynn Pulliam, Ph.D. National Cancer Institute Duke Cancer Institute Professor National Institutes of Health Duke University Medical Center Department of Laboratory Medicine and Medicine University of California, San Francisco Hans-Peter Kiem, M.D., F.A.C.P. Frank Maldarelli, M.D., Ph.D. Veterans Affairs Medical Center Full Member, Clinical Research Division Investigator Jose Carreras/E. Donnall Thomas Endowed HIV DRP Host-Virus Interaction Branch Lee Ratner, M.D., Ph.D. Chair for Cancer Research National Cancer Institute Professor Fred Hutchinson Cancer Research Center National Institutes of Health Department of Medicine Seattle, WA Washington University School of Medicine David M. Margolis, M.D. Scott Kitchen, Ph.D. Professor of Medicine, Microbiology and Andrew Rice, Ph.D. Assistant Professor of Medicine Immunology, and Epidemiology Professor Division of Hematology and Oncology School of Medicine Department of Molecular Virology and David Geffen School of Medicine University of North Carolina at Chapel Hill Microbiology University of California, Los Angeles Baylor College of Medicine Martin H. Markowitz, M.D. Richard Kornbluth, M.D., Ph.D. Professor and Clinical Director Charles Rinaldo, Ph.D. President and Chief Scientific Officer Aaron Diamond AIDS Research Center Professor and Chair Multimeric Biotherapeutics, Inc. Infectious Diseases and Microbiology Kenneth Hugh Mayer, M.D. University of Pittsburgh Richard A. Koup, M.D. Infectious Disease Attending & Director of HIV Deputy Director, Vaccine Research Center Prevention Research Melissa Robbiani, Ph.D. Chief, Immunology Laboratory Beth Deaconess Medical Center Senior Scientist and Director of Biomedical HIV National Institute of Allergy and Infectious Research Diseases Professor of Medicine Center for Biomedical Research National Institutes of Health Harvard Medical School Population Council

Nathaniel R. Landau, Ph.D. Medical Research Director, Co-Chair Ruth M. Ruprecht, M.D., Ph.D. Professor The Fenway Institute/Fenway Health Scientist, Department of Virology and Immunology Department of Microbiology Southwest National Primate Research Center New York University School of Medicine Joseph M. McCune, M.D., Ph.D. Director, Texas Biomed AIDS Research Program Professor of Medicine Texas Biomedical Research Institute Alan L. Landay, Ph.D. Chief, Division of Experimental Medicine Professor and Chairman University of California, San Francisco Sarah Schlesinger, M.D. Department of Immunology and Microbiology Associate Professor of Clinical Investigation Rush-Presbyterian-St. Luke’s Medical Center Donna Mildvan, M.D. Laboratory of Molecular Immunology Chief, Division of Infectious Diseases The Rockefeller University Michael Lederman, M.D. Department of Medicine Scott R. Inkley Professor of Medicine Beth Israel Medical Center Frederick A. Schmitt, Ph.D. Associate Director, Center for AIDS Research Professor Case Western Reserve University Jay A. Nelson, Ph.D. Departments of Neurology, Psychiatry, and Professor and Director Psychology and Behavioral Science Tun-Hou Lee, D.Sc. Vaccine and Gene Therapy Institute Sanders Brown Center on Aging Professor of Virology, Emeritus Oregon Health and Science University University of Kentucky Department of Immunology and Infectious Diseases Una O’Doherty, M.D., Ph.D. Gerald Schochetman, Ph.D. Harvard School of Public Health Associate Professor Senior Director, Diagnostics Research Department of Pathology and Laboratory Medicine Abbott Laboratories Michael J. Leibowitz, M.D., Ph.D. Perelman School of Medicine Professor, Medical Microbiology and Immunology University of Pennsylvania Robert Turner Schooley, M.D. University of California, Davis Academic Vice Chair Nancy Padian, Ph.D., M.P.H. Professor and Head Robert J. Levine, M.D. Adjunct Professor of Epidemiology Department of Medicine/Division of Infectious Professor of Medicine School of Public Health Diseases Center for Interdisciplinary Research on AIDS University of California, Berkeley University of California, San Diego Yale University

17 PROGRAM ADVISORY MANAGEMENT GROUP Gail Skowron, M.D. Professor of Medicine COUNCIL Boston University School of Medicine Mervyn F. Silverman, M.D., M.P.H. (Chairman) Kevin Robert Frost Serena Spudich, M.D., M.A. President Chief Executive Officer Associate Professor of Neurology Mervyn F. Silverman Associates Division Chief, Neurological Infections Crockett, CA Anthony Ancona and Global Neurology Vice President and Director, Human Resources Department of Neurology Judith D. Auerbach, Ph.D. Yale School of Medicine Science and Policy Consultant and Professor Susan J. Blumenthal, M.D., M.P.A. School of Medicine Senior Policy and Medical Advisor Leonidas Stamatatos, Ph.D. University of California, San Francisco Member Bradley Jensen Fred Hutchinson Cancer Research Center David Bloom, Ph.D. Chief Financial Officer Vaccine and Infectious Disease Division Clarence James Gamble Professor of Economics Rowena Johnston, Ph.D. Immunology and Vaccine Development Program and Demography Vice President and Director, Research Seattle, WA Department of Global Health and Population Harvard School of Public Health Jeffrey Laurence, M.D. Mario Stevenson, Ph.D. Boston, MA Senior Scientific Consultant for Programs Professor of Medicine Chief, Division of Infectious Diseases Tim Brown, Ph.D. John F. Logan, Ph.D., J.D. University of Miami Leonard M. Miller School Senior Fellow Vice President and General Counsel of Medicine The East-West Center Honolulu, HI Gregorio Millett, M.P.H. Vice President and Director, Public Policy Susana Valente, Ph.D. Daniel Douek, M.D., Ph.D. Associate Professor Chief, Human Immunology Section Eric Muscatell Department of Immunology and Microbial Vaccine Research Center Vice President, Development Sciences National Institute of Allergy and Infectious The Scripps Research Institute AnnMari Shannahan Diseases Vice President, Public Information Barbara Visscher, M.D., Dr.P.H. National Institutes of Health Professor of Epidemiology Annette Sohn, M.D. Daria J. Hazuda, Ph.D. Vice President and Director, TREAT Asia University of California, Los Angeles Vice President, Scientific Affairs for Infectious Disease David Vlahov, Ph.D., R.N. Merck & Company, Inc. Professor of Nursing, West Point, PA Epidemiology, and Biostatistics University of California, San Francisco Kenneth Hugh Mayer, M.D. Infectious Disease Attending & Director of HIV David J. Volsky, Ph.D. Prevention Research Professor of Medicine and Pathology Beth Israel Deaconess Medical Center Icahn School of Medicine at Mount Sinai Professor of Medicine Director of Molecular Virology Laboratory Harvard Medical School Department of Medicine Mount Sinai St. Luke’s and Roosevelt Hospitals Medical Research Director, Co-Chair The Fenway Institute/Fenway Health Steven S. Witkin, Ph.D. Mario Stevenson, Ph.D. Professor of Immunology Professor of Medicine Department of Obstetrics and Gynecology Chief, Division of Infectious Diseases Weill Cornell Medical College University of Miami Leonard M. Miller School of Peter R. Wolfe, M.D. Medicine Associate Clinical Professor Jeffrey L. Sturchio, Ph.D. David Geffen School of Medicine Senior Partner University of California, Los Angeles Rabin Martin New York, NY Steven Wolinsky, M.D. Professor Visiting Scholar Medicine/Infectious Diseases The Institute for Applied Economics, Global Health Feinberg School of Medicine and the Study of Business Enterprise Northwestern University Johns Hopkins University

Richard T. Wyatt, Ph.D. Member Professor of Immunology The Council on Foreign Relations IAVI Center for Neutralizing Antibodies Washington, D.C. The Scripps Research Institute Phill Wilson Jerome Zack, Ph.D. Chief Executive Officer and President Professor The Black AIDS Institute Department of Medicine Los Angeles, CA David Geffen School of Medicine University of California, Los Angeles

18 amfAR, The Foundation for AIDS Research

NEW YORK 120 Wall Street, 13th Floor New York, NY 10005-3908 (212) 806-1600 (tel) (212) 806-1601 (fax)

WASHINGTON, D.C. 1100 Vermont Avenue, NW Suite 600 Washington, DC 20005 (202) 331-8600 (tel) (202) 331-8606 (fax)

BANGKOK, THAILAND TREAT Asia Exchange Tower 388 Sukhumvit Road, Suite 2104 Klongtoey, Bangkok 10110 Thailand +66 (0)2 663 7561 (tel) +66 (0)2 663 7562 (fax)

www.amfar.org

amfAR meets the BBB Wise Giving Alliance’s Standards for Charity Accountability.